Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects for women with the diagnosis tend to be either very good or very bad.
Cells have two different programs to safeguard them from getting out of control and developing cancer. One of them is senescence (biological aging). It puts cancer cells into a permanent sleep so they no longer divide and grow in an uncontrolled way. Now the research group led by Professor Walter Birchmeier (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) has discovered that an…
The ‘MRI of the Adnexa, Essentials and Beyond’ session from at the MR 2015 symposium held in Garmisch, Austria, presented tips and tricks in clinical routine before moving to research that combines imaging and genomic data to better evaluate ovarian cancer. Report: John Brosky
Molecular profiling is transforming brain cancer management and radiologists must get to grips with the upcoming paradigm that will affect the way they report findings. Renowned neuroradiologist Professor Anne G. Osborn from the University of Utah, School of Medicine, Salt Lake City, unveiled the latest advances in brain pathology during the Nikola Tesla Honorary Lecture last week at ECR…
The mechanical basis of mitosis has only been understood in fragments so far. Scientists at Technische Universität Dresden have now been able to add another piece to the puzzle of cell biological mechanisms, as they report in the latest issue of the renowned scientific journal “Cell” .
A magnetic resonance spectroscopy (MRS) technique that monitors biochemical changes in tissue could improve the management of women at risk of breast cancer.
Women with metastatic breast cancer know they have a slim chance of long-term survival. The question is whether personalised therapy could extend their lives. Report: Cynthia E Keen
The term ‘cancer’ describes more than 200 different diseases and every single one needs to be clearly understood and requires, ideally, individual treatment. To do this we need to deepen our understanding the cancer genome. Report: Anja Behringer
In studies on prostate cancer, scientists from the German Cancer Research Center (DKFZ) simultaneously investigated the genetic and epigenetic development of the tumors.
Johns Hopkins researchers say they have discovered a chemical alteration in a single human gene linked to stress reactions that, if confirmed in larger studies, could give doctors a simple blood test to reliably predict a person’s risk of attempting suicide.
USA - Oocyte modification to eliminate inherited mitochondrial defects in a human embryo was the subject of a globally scrutinised Food and Drug Administration (FDA) hearing held in February.
‘The disease “cancer” is increasingly classified into sub-groups. Today, we are already dealing with a number of orphan diseases,’ says Professor Richard Greil MD, head of LIMCR at University Hospital Salzburg.
Down’s syndrome (also referred to as trisomy 21) is a genetic disorder caused by the presence of all or part of an extra copy of chromosome 21 in a person’s DNA. Current screening for Down’s syndrome and other trisomy conditions includes a combined test done between the 11th and 13th weeks of pregnancy.
Healthcare is undergoing a major change set to offer a real prospect of far more genetically targeted treatments, according a leading human geneticist Sir John Burn, Professor of Clinical Genetics at Newcastle University, England.
A British teenager, 17-year-old Fred Turner, has won a major accolade for building a DNA testing analyser in his own home for a few hundred euros.
More than half of Germany’s population aged between 18 and 74 years cannot show off a gapless set of teeth, and that’s similar in France and worse only in Poland, according to a 2012 study, which also investigated oral hygiene.
The international research project ‘The Definition of new types of tumours containing potential mutations sensitivity to drugs’ has begun in Petrov Research Institute of Oncology in St Petersburg, the oldest Russian oncology institute.
